NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

RecruitingN/A

Sponsor: Mayo Clinic

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

Interventions: Non-Interventional Study

Countries: United States

This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* 18 years of age or older
* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy
* One of the following:

  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment
  * Completed chemotherapy with no cardiotoxicity at least two years post treatment
  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity
* An understanding of the protocol and its requirements, risks, and discomforts
* The ability and willingness to sign an informed consent

Exclusion Criteria:

\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol

Locations (4)

Scottsdale, Arizona, United States
Jacksonville, Florida, United States
Tampa, Florida, United States
Rochester, Minnesota, United States